Practical considerations in the re-irradiation of recurrent and second primary head-and-neck cancer: Who, why, how, and how much? Journal Article


Authors: Chen, A. M.; Phillips, T. L.; Lee, N. Y.
Article Title: Practical considerations in the re-irradiation of recurrent and second primary head-and-neck cancer: Who, why, how, and how much?
Abstract: Despite progress in surgical and reconstructive techniques, as well as advances in radiotherapy delivery methods, a significant proportion of patients irradiated for head-and-neck cancer develop locoregional recurrence. These patients are also at high risk of developing new second primary cancers of the head and neck. Because of the heterogeneity of this population with respect to disease-related and patient-related factors, such as previous treatment, tumor recurrence site, disease extent, and performance status, the optimal treatment of locoregionally recurrent or second primary cancers of the head and neck remains to be defined. Although surgical resection typically constitutes the mainstay of treatment, effective salvage therapy is often precluded by anatomic inaccessibility and the risk of perioperative complications. Although chemotherapy alone has traditionally been considered an alternative to surgery, the response rates have been poor, with nearly all patients dying of disease progression within months. Similarly, salvage therapy using re-irradiation has historically been avoided because of concerns regarding toxicity. Although the results of more recent studies using contemporary treatment techniques and conformal delivery methods have been somewhat more promising, the role of re-irradiation after previous full-course radiotherapy is still considered investigational by many. Numerous questions remain unanswered, and practical guidelines for clinical decision-making are sparse. © 2011 Elsevier Inc.
Keywords: cancer surgery; disease course; review; intensity modulated radiation therapy; salvage therapy; cisplatin; erlotinib; fluorouracil; cancer risk; patient selection; capecitabine; paclitaxel; radiation dose; chemotherapy; methotrexate; recurrent cancer; follow up; tumor localization; carboplatin; metastasis; neoplasm recurrence, local; radiotherapy dosage; radiotherapy; practice guideline; cetuximab; cancer mortality; high risk patient; head and neck cancer; head and neck neoplasms; radiotherapy, intensity-modulated; disease progression; tumor recurrence; irradiation; surgical risk; surgery; clinical decision making; surgical resection; neoplasms, second primary; perioperative complication; head and neck; retreatment; diseases; performance status; head-and-neck cancer; recurrent; second primary; reirradiation; second primary cancer; response rate; locoregional recurrence; re-irradiation; delivery methods; optimal treatment; practical guidelines; treatment techniques
Journal Title: International Journal of Radiation Oncology, Biology, Physics
Volume: 81
Issue: 5
ISSN: 0360-3016
Publisher: Elsevier Inc.  
Date Published: 2011-12-01
Start Page: 1211
End Page: 1219
Language: English
DOI: 10.1016/j.ijrobp.2011.06.1998
PROVIDER: scopus
PUBMED: 22115554
DOI/URL:
Notes: --- - "Export Date: 3 January 2012" - "CODEN: IOBPD" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Nancy Y. Lee
    878 Lee